ADMA Biologics Inc vs ProShares Bitcoin ETF — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while ProShares Bitcoin ETF trades at $8.6. The key difference: ADMA Biologics Inc is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| ADMA | BITO | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Crypto-linked |
52-Week High | $20.38 | $22.27 |
52-Week Low | $7.60 | $7.98 |
Enterprise Value | $2.25B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
BITO trades at $8.79, up 1.03% with a bullish technical signal from moving averages. The ETF maintains a consistent dividend distribution pattern with recent $0.01 payouts. Technical indicators show neutral oscillators but overall positive momentum, with support and resistance clustered around $9. The fund's performance reflects ongoing investor interest in Bitcoin exposure vehicles despite market volatility.
BITO faces structural challenges with higher fees impacting long-term returns compared to spot Bitcoin ETFs. Recent analyst coverage highlights tactical utility but questions buy-and-hold suitability. The fund's correlation breakdown with high-beta equities and persistent crypto market headwinds present significant risk factors for investors seeking sustained growth.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →